Literature DB >> 30822445

Functional Changes of Retinal Ganglion Cells and Visual Pathways in Patients with Chronic Leber's Hereditary Optic Neuropathy during One Year of Follow-up.

Vincenzo Parisi1, Lucia Ziccardi2, Federico Sadun3, Anna Maria De Negri4, Chiara La Morgia5, Lucilla Barbano1, Valerio Carelli5, Piero Barboni6.   

Abstract

PURPOSE: To assess changes of retinal ganglion cells (RGCs) and visual pathways' function in patients with Leber's hereditary optic neuropathy (LHON) during 12 months of follow-up of the chronic phase.
DESIGN: Retrospective case series. PARTICIPANTS: Twenty-two patients with LHON (mean age, 36.3±9.3 years) in the "chronic phase" of the disease, providing 42 eyes (LHON group) with different pathogenic mitochondrial DNA mutations (group 11778: 21 eyes; group 3460: 4 eyes; group 14484: 13 eyes; and group 14568: 4 eyes) were enrolled. Twenty-five age-similar healthy participants, providing 25 eyes, served as controls.
METHODS: Pattern electroretinogram (PERG) and visual evoked potentials (VEP), in response to 60' and 15' checks visual stimuli, were recorded at baseline in all subjects and after 6 and 12 months of follow-up in patients with LHON. At baseline, in all LHON eyes for each PERG and VEP parameter (amplitude and implicit time), the 95% confidence limit (CL) of test-retest variability was calculated. The PERG and VEP mean values observed in LHON eyes were compared (1-way analysis of variance [ANOVA]) with those of controls. During the follow-up, the PERG and VEP differences observed with respect to baseline were evaluated by ANOVA. MAIN OUTCOME MEASURES: Changes of individual and mean absolute values of 60' and 15' PERG amplitude and VEP amplitude and implicit time at each time point compared with baseline values in the LHON group.
RESULTS: At baseline, mean values of PERG and VEP parameters detected in the LHON group were significantly (P < 0.01) different with respect to control values. In the LHON group, at 6 and 12 months of follow-up, the majority of eyes showed unmodified (within 95% CL) PERG and VEP values, and mean absolute values of these measures were not significantly (P > 0.01) different from baseline values.
CONCLUSIONS: In our untreated patients with chronic LHON, with different specific pathogenic mutations, RGCs and visual pathways function were not significantly modified during 12 months of follow-up. This should be considered in the disease natural history when attempts for treatments are proposed in chronic LHON.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30822445     DOI: 10.1016/j.ophtha.2019.02.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Correlations between visual morphological, electrophysiological, and acuity changes in chronic non-arteritic ischemic optic neuropathy.

Authors:  Lucilla Barbano; Lucia Ziccardi; Vincenzo Parisi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-07       Impact factor: 3.117

2.  Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis.

Authors:  Lucia Ziccardi; Lucilla Barbano; Laura Boffa; Maria Albanese; Carolina Gabri Nicoletti; Doriana Landi; Andrzej Grzybowski; Benedetto Falsini; Girolama Alessandra Marfia; Diego Centonze; Vincenzo Parisi
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

3.  The Relationship Between Stage of Leber's Hereditary Optic Neuropathy and Pattern Electroretinogram Latency.

Authors:  Vittorio Porciatti; Diego E Alba; William J Feuer; Janet Davis; John Guy; Byron L Lam
Journal:  Transl Vis Sci Technol       Date:  2022-03-02       Impact factor: 3.283

4.  Visual Evoked Potentials in Joubert Syndrome: A Suggested Useful Method for Evaluating Future Approaches Targeted to Improve Visual Pathways' Function.

Authors:  Giulio Ruberto; Vincenzo Parisi; Chiara Bertone; Sabrina Signorini; Mauro Antonini; Enza Maria Valente; Federica Manzoni; Valentina Serpieri; Riccardo Fausto; Luciano Quaranta
Journal:  Adv Ther       Date:  2020-10-24       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.